S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Are "The Magnificent Seven" the Next Sears? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Are "The Magnificent Seven" the Next Sears? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Are "The Magnificent Seven" the Next Sears? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Are "The Magnificent Seven" the Next Sears? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Are "The Magnificent Seven" the Next Sears? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Are "The Magnificent Seven" the Next Sears? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Are "The Magnificent Seven" the Next Sears? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Are "The Magnificent Seven" the Next Sears? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

$43.56
-1.79 (-3.95%)
(As of 09/29/2023 ET)
Compare
Today's Range
$43.05
$46.00
50-Day Range
$27.80
$45.35
52-Week Range
$27.30
$101.30
Volume
1.32 million shs
Average Volume
1.40 million shs
Market Capitalization
$2.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.85

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.54 Rating Score
Upside/​Downside
28.2% Upside
$55.85 Price Target
Short Interest
Bearish
15.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
0.82mentions of Mirati Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$33.70 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($11.85) to ($10.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

139th out of 972 stocks

Pharmaceutical Preparations Industry

47th out of 455 stocks


MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX Price History

MRTX Stock News Headlines

Mirati Therapeutics (NASDAQ:MRTX) Shares Down 3.7%
Investing Legend Warns: NVIDIA is a "Delusion"
Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.
Mirati Therapeutics (NASDAQ:MRTX) Sees Strong Trading Volume
Massive Insider Trade At Mirati Therapeutics
Investing Legend Warns: NVIDIA is a "Delusion"
Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.
Scotiabank Keeps Their Sell Rating on Mirati Therapeutics (MRTX)
Mirati Therapeutics CFO Laurie Stelzer Resigns
JMP Securities Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
3 Under-the-Radar Biotech Stocks to Buy in 2023
Piper Sandler Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
Mirati Therapeutics (MRTX) Has a New Rating from Barclays
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
587
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$55.85
High Stock Price Forecast
$83.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+28.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
13 Analysts

Profitability

Net Income
$-740,870,000.00
Net Margins
-2,709.33%
Pretax Margin
-2,707.47%

Debt

Sales & Book Value

Annual Sales
$12.44 million
Book Value
$17.31 per share

Miscellaneous

Free Float
56,570,000
Market Cap
$2.55 billion
Optionable
Optionable
Beta
0.91

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Charles M. Baum M.D. (Age 65)
    Ph.D., Founder, Interim CEO, Pres, Head of R&D and Director
    Comp: $1.07M
  • Dr. James G. Christensen Ph.D. (Age 55)
    Exec. VP & Chief Scientific Officer
    Comp: $1.76M
  • Ms. Laurie D. Stelzer M.B.A. (Age 55)
    Consultant
    Comp: $609.06k
  • Dr. Alan Bart Sandler M.D. (Age 66)
    Exec. VP & Chief Medical Officer
    Comp: $591k
  • Mr. Aaron Ondrey (Age 47)
    Interim Chief Financial Officer
  • Ms. Betsy Gelfand CPA
    Chief Accounting Officer, Principal Accounting Officer & VP of Fin.
  • Mr. John B. Moriarty Jr. (Age 55)
    J.D., Chief Legal Officer
  • Mr. Peter Lee
    Chief Compliance Officer
  • Mr. Michael E. Paolucci (Age 63)
    Chief People Officer
  • Mr. Benjamin J. Hickey M.B.A. (Age 48)
    Chief Commercial Officer













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

13 Wall Street research analysts have issued twelve-month target prices for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $31.00 to $83.00. On average, they expect the company's share price to reach $55.85 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2023?

Mirati Therapeutics' stock was trading at $45.31 at the beginning of the year. Since then, MRTX shares have decreased by 3.9% and is now trading at $43.56.
View the best growth stocks for 2023 here
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($3.04) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.19. The biotechnology company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $13.17 million. Mirati Therapeutics had a negative net margin of 2,709.33% and a negative trailing twelve-month return on equity of 79.37%. The firm's quarterly revenue was up 153.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.18) EPS.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $43.56.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.55 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.82) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 587 workers across the globe.

Does Mirati Therapeutics have any subsidiaries?
The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -